Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.60 |
| ▸ | CHIT1 | Q13231 | 6/20 | 0.55 |
| ▸ | CHIA | Q9BZP6 | 6/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | CHI3L1 | P36222 | 1/20 | 0.46 |
| ▸ | CHI3L2 | Q15782 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | LSS | P48449 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16825796 | 0.89 | CHIA (0.53) | TAAR1CHIT1CHIASIGMAR1CHI3L1 | |
| SCHEMBL1967611 | 0.83 | CHIA (0.54) | TAAR1CHIT1CHIASIGMAR1CHI3L1 | |
| SCHEMBL1968987 | 0.83 | CHIA (0.54) | TAAR1CHIT1CHIASIGMAR1CHI3L1 | |
| SCHEMBL1969047 | 0.81 | TAAR1 (0.60) | TAAR1CHIT1CHIASIGMAR1CHI3L1 | |
| SCHEMBL27817745 | 0.81 | CHIT1 (0.63) | TAAR1CHIT1CHIASIGMAR1CHI3L1 | |
| SCHEMBL27817743 | 0.81 | HTR2A (0.49) | CHIT1CHIACHI3L1CHI3L2GRIN2B | |
| SCHEMBL1967143 | 0.81 | GRIN2B (0.63) | TAAR1CHIASIGMAR1GRIN2BHTR2A | |
| SCHEMBL1239203 | 0.81 | HRH3 (0.59) | TAAR1SIGMAR1GRIN2BLSS | |
| SCHEMBL27837194 | 0.80 | TAAR1 (0.65) | TAAR1CHIT1CHIASIGMAR1GRIN2B | |
| SCHEMBL1966648 | 0.79 | TAAR1 (0.47) | TAAR1CHIT1CHIACHI3L1CHI3L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2151447-A1 | LINCOMYCIN DERIVATIVES AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Meiji Seika Kaisha Ltd. (JP) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | LAS1L, LCLAT1, LYPLA1 | TAAR1 4340/4885CHIT1 259/4885CHIA 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.